|

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

RECRUITINGSponsored by University of Colorado, Denver
Actively Recruiting
SponsorUniversity of Colorado, Denver
Started2017-06-22
Est. completion2027-06
Eligibility
Age45 Years – 90 Years
Healthy vol.Accepted
Locations1 site

Summary

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.

Eligibility

Age: 45 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

1. ≥ 45years old
2. Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria

Exclusion Criteria:

1. Inability to give informed consent
2. Pregnant women
3. History of interstitial lung disease
4. Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc.
5. Subjects over the age of 90 years old or less than 45 years old

Conditions3

ArthritisInterstitial Lung DiseaseRheumatoid Arthritis

Locations1 site

University of Colorado - Anschutz Medical Campus
Aurora, Colorado, 80045
Haylie A Lengel970-376-8303haylie.lengel@cuanschutz.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.